Clinical Evaluation of Patients With X-linked Retinoschisis

Exclusion Criteria

• •Main Study:
• •Other eye diseases that might affect the results (e.g. history of retinal detachment, glaucoma, cataracts that prohibit imaging, or any other eye pathology that in the opinion of the investigator would preclude enrollment)
• •CAI Sub-study:
• •Already being treated with CAIs
• •Previous documented failure to respond to CAI treatment
• •Any drug-specific contraindication/precaution listed below (from www.micromedex.com):
• •Topical Eye Drop Dorzolamide Hydrochloride
• •Contraindications:
• •hypersensitivity to dorzolamide products, including sulfa allergies
• •Precautions:
• •dorzolamide is a sulfonamide that is absorbed systemically, sulfonamide hypersensitivity reactions may occur
• •angle-closure glaucoma
• •concomitant use of oral carbonic-anhydrase inhibitors
• •conjunctivitis and lid reactions reported with chronic administration
• •moderate to severe renal (CrCl less than 30 mL/min) or hepatic insufficiency
• •ocular infection or inflammation
• •recent ocular surgery
• •Topical Eye Drop Brinzolamide
• •Contraindications:
• •hypersensitivity to any component of the product, including sulfa allergies
• •Precautions:
• •concomitant use of oral carbonic anhydrase inhibitors is not recommended
• •contact lens use; remove contact lenses prior to administration, allow 15 minutes before reinsertion
• •hypersensitivity to sulfonamides; severe reaction may occur; discontinue if signs or symptoms appear
• •low corneal endothelial cell counts; increased risk of corneal edema
• •renal impairment, severe (CrCl less than 30 mL/min); use not recommended